Full Title
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination with Weekly Carfilzomib and Dexamethasone in Adult Participants with Relapsed and/or Refractory Multiple Myeloma (RRMM)Purpose
Researchers are assessing a new way of giving isatuximab with carfilzomib and dexamethasone in people with multiple myeloma. Isatuximab is injected under the skin using a wearable device attached to the skin of the stomach area. Carfilzomib will be given intravenously (by vein). Dexamethasone can be taken orally (by mouth) or intravenously.
All three drugs are already used together to treat multiple myeloma that comes back or resists other treatments. Researchers also want to see if shortening the treatment time compared to the usual approach works well and gives patients more flexibility.
Contact
For more information or to see if you can join this study, please call Dr. Carlyn Rose Tan’s office at 646-608-3778.
Protocol
24-380
Phase
Phase II (phase 2)
Disease Status
Relapsed or Refractory
Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06356571
ClinicalTrials.gov